Bain Capital Life Sciences said Tuesday it has secured about $3 billion for its fourth fund, bringing the private investment firm’s total haul since its 2016 inception to $6.7 billion.

贝恩资本生命科学（Bain Capital Life Sciences）周二表示，其第四只基金已获得约30亿美元资金，使这家私人投资公司自2016年成立以来的总收益达到67亿美元。

Bain Capital said the new fund includes $2.5 billion of outside commitments from new and existing investors, with the remainder coming from its partners, employees and affiliates. The firm said it intends to use the cash to back companies working on therapeutics, medical devices, life science tools and diagnostics that will “improve the lives of patients with unmet medical needs.”.

贝恩资本表示，新基金包括来自新投资者和现有投资者的25亿美元外部承诺，其余资金来自其合作伙伴、员工和附属公司。该公司表示，它打算用这笔资金支持从事治疗、医疗设备、生命科学工具和诊断的公司，这些公司将“改善医疗需求未得到满足的患者的生活”。

Since being formed eight years ago, Bain Capital’s life sciences arm has invested in more than 70 companies that have achieved 16 regulatory approvals. The firm invests in new companies, provides growth funding for more advanced startups and also financial lifelines to “fallen angels” it deems to be at a crossroads.

自八年前成立以来，贝恩资本的生命科学部门已投资了70多家公司，这些公司已获得16项监管批准。该公司投资新公司，为更先进的初创公司提供增长资金，并为其认为处于十字路口的“堕落天使”提供财务生命线。

It has had success investing in spin-outs of pharmaceutical companies, too. Springworks Therapeutics and Cerevel Therapeutics, for instance, were each built around medicines that originated at Pfizer. Springworks eventually went public and last year brought a drug for desmoid tumors to market. Cerevel, meanwhile, was acquired by AbbVie for $8.7 billion..

它也成功地投资了制药公司的螺旋输出（spin out）。例如，Springworks Therapeutics和Cerevel Therapeutics都是围绕辉瑞公司生产的药物而开发的。Springworks最终上市，去年将一种治疗硬纤维瘤的药物推向市场。与此同时，Cerevel以87亿美元被AbbVie收购。。

The new fundraise follows a string of buyouts involving some of Bain’s portfolio companies that were private at the time of their acquisition. This year alone, Aiolos Bio, Jnana Therapeutics and EyeBio were acquired by large drugmakers, part of a recent uptick in M&A deals for biotech startups.

此次新的筹资活动之前，贝恩的一些投资组合公司进行了一系列收购，这些公司在收购时是私人的。仅在今年，Aiolos Bio、Jnana Therapeutics和EyeBio就被大型制药商收购，这是最近生物技术初创公司并购交易增加的一部分。

Amid a stabilization of biotech venture funding, the firm has also continued to invest in some of the sector’s larger funding rounds, among them a $260 million financing for Cardurion Pharmaceuticals last month and a $400 million raise in May for an obesity drug startup tentatively called Hercules CM NewCo..

在生物技术风险投资稳定的情况下，该公司还继续投资于该行业的一些较大的融资回合，其中上月为Cardurion Pharmaceuticals提供了2.6亿美元的融资，5月为一家肥胖药物初创公司（暂定名为Hercules CM NewCo）筹集了4亿美元。。

Bain Capital previously raised $1.9 billion for its third fund three years ago.

贝恩资本三年前为其第三只基金筹集了19亿美元。